Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
NCT06626256 · City of Hope Medical Center · PHASE1 · withdrawn · last registry update 2025-12-24 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no resource” | Open Targets' class: logistics resources | Registry record, City of Hope Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-01Also stopped (terminated): Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, TCR-T therapy (NCT05438667)
- 2026-05-19Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT03745326)
- 2026-05-19Also stopped (terminated): National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT03745326)
- 2025-09-11Also stopped (withdrawn): National Cancer Institute (NCI), KRAS TCR-Transduced PBL + Aldesleukin (NCT06690281)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision